OncRef

Clinical Trial: NCT03517137

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:European Organisation for Research and Treatment of Cancer - EORTC
Information Provided By:European Organisation for Research and Treatment of Cancer - EORTC
Last Update Posted:2026-09-11

Study Overview

Brief Summary

The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens.

Official Title

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Conditions

Advanced Hodgkin Lymphoma

Intervention / Treatment

  • Drug: Brentuximab Vedotin
  • Drug: Adriamycin
  • Drug: Vinblastine
  • Drug: Dacarbazine
  • Drug: Etoposide
  • Drug: Cyclophosphamide
  • Radiation: Radiation Therapy

Other Study ID Numbers

  • EORTC-1537-LYMG

Start Date (Actual)

2019-08-01

Primary Completion Date (Actual)

2023-08-28

Study Completion Date (Estimated)

2026-11-16

Enrollment (Actual)

150

Study Type

Interventional

Phase

Phase 2